Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective

ObjectiveAge adjusted incidence rate for uterine cancers in Norway has increased over last three decades from 12.2/100.000 (1981–90) to 16.0 (2001–2010). Corresponding 5-year survival increased nationally from 76.3% to 83.3%.MethodsWe wanted to investigate how changes in therapeutic strategies during a 30-year period are reflected in survival changes through careful characterization of a population-based series of 1077 endometrial carcinoma patients from Hordaland County, Norway.ResultsIn concordance with increase in endometrial cancer nationally, the number of patients treated from Hordaland County rose from 286 (1981–1990) through 307 (1991–2000) to 484 (2001–2010). Main treatment changes included increase in routine pelvic lymphadenectomy from 0% through 9% to 77%, adjuvant chemotherapy from 0% through 3% to 9% and a dramatic reduction in adjuvant radiotherapy from 75% through 48% to 12% (all P < 0.001). Body mass index increased significantly during this 30-year period, as did the 5-year disease-specific survival: from 75.8 through 80.2 to 86.9% (P = 0.002) and overall survival from 67.8 through 71.7 to 77.8% (P = 0.03).ConclusionImproved overall and disease specific survival for endometrial carcinoma patients over the last 30 years is demonstrated in a population-based setting. Increasing BMI among patients and a change in treatment strategy with reduction in adjuvant radiotherapy and more extensive surgery is demonstrated for the same period.

► Endometrial cancer patients had a 10% improved survival during the last 30 years.
► The use of adjuvant radiation therapy was reduced from 75% to 12%.
► More patients were subjected to extensive surgery despite increasing BMI.